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A sensitive and reliable ultra fast liquid chromatography tandem mass spectrometry
(UFLC-MS/MS) method has been developed and validated for simultaneous quantitation of
alisol A and alisol B 23-acetate from Alisma orientale (Sam.) Juz. in rat plasma using
diazepam as an internal standard (IS). The plasma samples were extracted by liquideliquid
extraction with methyl tert-butyl ether and separated on a Venusil MP C18 column
(100 mm  2.1 mm, 3.0 mm) (Venusil, China) using gradient elution with the mobile phase
consisting of methanol and 0.1% acetic acid in water at a flow rate of 0.4 ml/min. The two
analytes were monitored with positive electrospray ionization by multiple reaction
monitoring mode (MRM). The lower limit of quantitation was 5.00 ng/ml for alisol A and
5.00 ng/ml for alisol B 23-acetate. The calibration curves were linear in the range of 5.00
e2500 ng/ml for alisol A and 5e2500 ng/ml for alisol B 23-acetate. The mean extraction
recoveries were above 63.8% for alisol A and 68.0% for alisol B 23-acetate from biological
matrixes. Both intra-day and inter-day precision and accuracy of analytes were well within
acceptance criteria (15%). The validated method was successfully applied to the pharma-
cokinetic study of alisol A and alisol B 23-acetate in rat plasma after oral administration of
alcohol extract of Alismatis Rhizoma.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.Shenyang Pharmaceutical University, Shenyang 110016, China. Tel./fax: þ86 024 23986012.
(K. Bi).
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Alisma orientale (Sam.) Juz. (Alismataceae) is distributed in
China, Japan, Mongolia and Russia [1]. The dried rhizome of
this plant is a common traditional Chinese medicine, known
as Alismatis Rhizoma (Zexie in Chinese) with the function of
removing dampness and promoting water metabolism ac-
cording to the theory of Traditional Chinese Medicine [2].
Alismatis Rhizoma has been commonly used for the treat-
ment of various diseases, including hyperlipidemia, diabetes,
hypertension, and urological diseases [3e5]. Protostane-type
triterpenes are the principal active constituents of Alismatis
Rhizoma and more than 50 unique protostane-type tri-
terpenes have been isolated from this herbal drug [6e8]. As the
bioactive “marker compounds” of Alismatis Rhizoma, alisol A
and alisol B 23-acetate (Fig. 1), which are the two major active
triterpenoid compounds isolated from Alismatis Rhizoma,
have particularly been the focus of research in recent years
because of their relatively high levels in Alismatis Rhizoma
and various pharmacological activities. They were demon-
strated to possess diuretic, anti-inflammatory, anti-allergic
effects, and hypocholesterole-mic effects [9e11]. Further-
more, it has been demonstrated that alisol B 23-acetate in-
duces cell death of hepatoma and leukemia cells [12,13].
However, as far as we are aware, there are few reports on
the pharmacokinetic study of alisol A and alisol B 23-acetate,
despite that the study of the pharmacokinetics is essential to
illuminate the mechanism of action. In previous studies, the
pharmacokinetics of Alismatis Rhizoma was evaluated by
HPLC and LC-MS methods [14e16]. The previous experimentsFig. 1 e Chemical structures of alisol A (a), alisol B
23-acetate (b), and diazepam (IS) (c).had shown that HPLC and LC-MS did not provide satisfactory
lower limits of quantification (LLOQ) and also took long anal-
ysis time.While the UFLC-MS/MSmethod can overcome these
barriers, it is more fast, selective and sensitive. Thus, a UFLC-
MS/MSmethod for the simultaneous determination of alisol A
and alisol B 23-acetate in rat plasma after oral administration
of Alismatis Rhizoma extract has been developed and vali-
dated for the first time in the work discussed in this paper.
This will be helpful for improving clinical therapeutic efficacy
and further pharmacological studies of alisol A and alisol B
23-acetate, meanwhile it can facilitate the further research
and reasonable usage of Alismatis Rhizoma.2. Materials and methods
2.1. Chemicals and materials
The dried rhizomes of Alisma orientale (Sam.) Juz. were pur-
chased from Shenyang Tongrentang Drug Company (She-
nyang, China) and identified by associate professor Ying Jia
(Department of Traditional Chinese Medicine, Shenyang
Pharmaceutical University, Shenyang, China). Alisol A (purity
>98%) and alisol B 23-acetate (purity >98%) were purchased
from Chengdu Must Biotechnology Co.Ltd (Chengdu, People's
Republic of China). Diazepam (purity >98%) (Fig. 1), used as the
internal standard (IS) was purchased from the National
Institute for Control of Pharmaceutical and Biological Products
(Beijing, China). Acetonitrile andmethanol (high-performance
liquid chromatography (HPLC) grade) were obtained from
Fisher Scientific (Fair Lawn, NJ, USA). HPLC grade reagents
such as acetic acid, methyl tert-butyl ether were provided by
Shandong Yuwang Industrial Co.Ltd. (Yucheng, China). All
other reagents were of analytical purity. Distilled water pre-
pared with demineralized water was employed throughout
the experiment.
2.2. Animals
Six male pathogen-free Sprague-Dawley rats (220e250 g) were
obtained from the Experimental Animal Center of Shenyang
Pharmaceutical University (Shenyang, People's Republic of
China). The animal study was carried out in accordance with
the Guideline for Animal Experimentation of Shenyang Phar-
maceutical University, and the protocol was approved by the
Animal Ethics Committee of the institution.
2.3. Instrumentation and chromatographic conditions
The UFLC-ESI-MS/MS system was performed using an XR LC-
20AD Prominence™ UFLC system equipped with a binary
pump, a degasser, an autosampler and a thermostatted col-
umn compartment (Shimadzu, Japan) and aQTRAP™ 4000MS/
MS system from Applied AB Sciex equipped with a turbo ion
spray source (Foster City, CA, USA). All the operations, the
acquiring and analysis of data were controlled by Analyst
(version 1.6, AB Sciex, USA).
The compounds were separated on a Venusil MP C18 col-
umn (100mm 2.1mm, 3.0mm) (Venusil, China) protected by
a high pressure column pre-filter (2 mm) (Shimadzu, Japan) at
Table 1e List of selectedMRMparameters, declustering potential (DP), entrance potential (EP), collision energy (CE), and cell
exit potential (CXP) for each analyte and IS.
Analyte Q1Mass(Da) Q3Mass(Da) DP(V) EP(V) CE(V) CXP(V)
Alisol A 491.3 383.4 120 10 17 12.6
Alisol B 23-acetate 515.6 437.5 120 10 21.8 10
Diazepam 284.7 193.1 80 10 43 10
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0.1% acetic acid in water (B). The 8.0 min UFLC gradient pro-
gram was as follows: 80% A / 100% A at 0.01 / 4.00 min;
100% A at 4.01/ 5.00 min; 80% A at 5.01/ 8.00 min. Efficient
and symmetrical peaks were obtained at a flow rate of 0.4 ml/
min with a sample injection volume of 5 ml.
The detection of the analytes was in the multiple reaction
monitoring mode (MRM) using an electrospray positive ioniza-
tion (ESIþ). The electrospray source and themass spectrometer
were adjusted to the following parameters: curtain gas, 20 psi;
gas 1, 50 psi; gas 2, 50 psi (all gases: nitrogen) with a source
temperature of 500 C. The ion spray voltage was set at 5500 V
for positive monitoring. The main MS parameters are listed in
Table 1.2.4. Preparation of Alismatis Rhizoma extract
The crude drug (100 g) was extracted twice by refluxing with
95% ethanol (1:10, w/v), 1 h for each time. After removing the
ethanol under reduced pressure, the residue was dissolved in
aqueous solution of 0.5%CMC-Na to get theAlismatis Rhizoma
extract with an Alismatis Rhizoma concentration of 2 g/ml
(containing 1.4 mg/g alisol A and 0.6 mg/g alisol B 23-acetate).2.5. Preparation of standard solution
The stock solution of alisol A, alisol B 23-acetate and diazepam
(IS) were prepared in acetonitrile at the concentration of
500.0 mg/ml, 100.0 mg/ml and 10.0 mg/ml, respectively. They
were furtherdilutedwithacetonitrile tomakea series ofmixed
working solutions at the concentration of 40.0e200*e4 ng/ml
for alisol A and40.0e200*e4ng/ml for alisol B 23-acetate; ISwas
diluted to a concentration of 50.0 ng/ml with acetonitrile as
working solution. All the stocks were stored at 4 C.2.6. Sample preparation
All the plasma samples were extracted by liquideliquid
extraction technique. Aliquots (200 ml) of plasma were spiked
with 25 ml of IS, 25 ml of methanol and 20 ml of 1% acetic acid by
vortexing for 30 s, then themixture were extracted with 800 ml
of methyl tert-butyl ether by vortex-mixing for 3 min. After
centrifugation at 13,000 rpm, 4 C for 8 min, the organic layer
was quantitatively transferred to a clean centrifuge tube and
evaporated to dryness under a gentle stream of nitrogen at
room temperature. The residuewas reconstitutedwith 50 ml of
methanol and vortex-mixed for 3 min, then sonicated for
3 min followed by being centrifuged at 13,000 rpm for 5 min;
finally, an aliquot of 5 ml of the solution was injected into the
LC-MS/MS system for analysis.2.7. Method validation
Themethodwas validated according to the currently accepted
US-FDA Bioanalytical Method Validation Guidance and Euro-
pean Medicines Agency Guideline on Bioanalytical Method
Validation with respect to selectivity, matrix effect, lower
limit of quantification, calibration curve, accuracy and preci-
sion, recovery and stability [17].
Selectivity was assessed by comparing chromatograms
obtained from six different batches of blank plasma of six rats,
with those obtained from corresponding standard plasma
samples spiked with analytes, IS, and a plasma sample after
oral administration of Alismatis Rhizoma extract. The matrix
effect wasmeasured at three QC levels by comparing the peak
response of blank plasma extracts spikedwith the analytes (A)
with that of pure standard solution containing equivalent
amounts of the compounds (B). The ratio (A/B  100)% was
used to evaluate the matrix effect.
The linearity of the assay was assessed by analyzing the
calibration curves of alisol A (5.00, 10.00, 20.00, 100.0, 500.0,
1000 and 2500 ng/ml) and alisol B 23-acetate (5.00, 10.00, 50.00,
250.0, 500.0, 1250, 2500 ng/ml) in plasma using least-squares
linear regression of the analyte-to-IS peak-area ratios versus
the nominal concentration of the calibration standard with a
weighed factor (1/x2). The lower limit of quantification (LLOQ)
was defined as the lowest concentration on the calibration
curve with acceptable accuracy within ±20% and precision
below 20%.
Quality control sample (QC samples) at low, medium and
high concentrations (at 25.00, 300.0, and 4000 ng/ml for alisol
A and 12.50, 150.0, and 2000 ng/ml for alisol B 23-acetate) were
analyzed on three separate occasions with six replicates at
each concentration per occasion to determine accuracy and
precision. Precision was expressed as the relative standard
deviation (RSD, %) and accuracy was defined as relative
error (RE, %). The recoveries of alisol A and alisol B 23-acetate
were determined at three QC levels with six replicates by
comparing the peak response from extracted samples (C)
with those from post-extracted blank plasma samples spiked
with the analytes (A) at the same concentration. The ratio
(C/A  100)% was used to evaluate the recovery. Recovery of
the ISwas determined in the sameway at the concentration of
5.00 ng/ml.
2.8. Stability testing
Stability studies in plasma samples were also conducted at
three QC levels under several different storage conditions: at
room temperature for 24 h, at 20 C for at least 7 days, after
three freeze-thaw cycles, and 8 h after prepare at 4 C during
the analysis process.
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All of the six rats were fasted for 12 h, with free access towater
prior to the experiments. After giving 25 g/kg of Alismatis
Rhizoma extract (calculated by crude drug) to each rat orally,
the blood samples (0.3ml) obtained from the oculi chorioideae
vein of rats at 0, 0.17, 0.33, 0.75, 1, 1.5, 2, 4, 6, 7, 9, 12, 24, and
36 h were placed in heparinized tubes and separated by
centrifugation at 4000 rpm for 5 min. The separated plasma
samples were finally stored at 20 C until analysis.
The pharmacokinetic analysis of the two analytes was
performed by a non-compartmental approach using the DAS
2.1 software package (Chinese Pharmacological Society) to
calculate AUC and T1/2. Cmax and Tmax were obtained directly
from plasma concentrationetime curve.Fig. 2 e The product ion mass spectra of alisol A (a) (m/z
491.5/383.4), alisol B 23-acetate (b) (m/z 515.6/437.5), and
diazepam (IS) (c) (m/z 284.7/193.1).3. Results and discussion
3.1. Optimization of mass and chromatographic
conditions
Under the chosen electrospray ionization conditions, greater
sensitivity was achieved for alisol A, alisol B 23-acetate and
diazepam in the positive mode than the negative mode. The
full-scan product ion spectrums of analytes by infusing the
standard solutions into the mass spectrometer are shown as
Fig. 2. Some parameters such as gas1, gas2, curtain gas, IS
Voltage,DP, CE andCXPwere optimized. The other parameters
were adopted for the recommended value of the instrument.
The mobile phase played an important role in improving
peak shape, detection sensitivity and shortening analysis
time. The methanolewater and acetonitrileewater systems
were investigated. Methanol was used as the organic modifier
because it provided higher responses and lower background
noise than acetonitrile. With addition of acetic acid to the
mobile phase, peak symmetry for both alisol A, alisol B 23-
acetate and diazepam was improved. Then 0.05%, 0.1% and
0.2% acetic acid were investigated. 0.1% and 0.2% acetic acid
were better than 0.05% acetic acid in the peak symmetry of the
analytes, and there was no significant difference between
0.1% and 0.2% acetic acid. The gradient program in the work
provided good resolution and shorter analysis time. Finally,
methanole0.1% acetic acidwith appropriate gradient program
was adopted as the mobile phase for sufficient ionization
response, good peak symmetry, and proper retention time for
the analytes and IS.
3.2. Sample preparation
Liquideliquid extraction was investigated in our study. The
extractant and pH of buffer play a vital role in liquideliquid
extraction (LLE) method. Among the organic solvents such as
methyl tert-butyl ether, ethyl acetate and diethyl ether,
methyl tert-butyl ether gave the highest recovery for both
alisol A and alisol B 23-acetate. 800 ml, 1000 ml, 1600 ml and
2000 ml of methyl tert-butyl ether was added to 200 ml of
plasma samples respectively.With the amount ofmethyl tert-
butyl ether increasing, there was no significant difference in
extraction recovery, so 800 ml was chosen. Moreover additionof acetic acid in the extraction procedure increased the re-
covery of the analytes, whereas there was no obvious increase
above 20 ml 1% acetic acid. Finally, the addition of 20 ml of 1%
acetic acid and 800 ml of methyl tert-butyl ether into 200 ml of
plasma was determined because it provided high recoveries
for both the analytes and the IS.
3.3. Method validation
3.3.1. Selectivity and matrix effect
No significant interference or ion suppressionwas observed at
the retention times of alisol A (3.00 min), alisol B 23-acetate
(3.17 min), and IS (1.42 min). With the help of UFLC system,
high selectivity of MRM mode and appropriate mobile phase,
typical chromatograms obtained from blank plasma, blank
plasma spiked with analytes and IS, and a rat plasma sample
Fig. 3 e A, B and C show the MRM chromatograms of a blank plasma sample, blank plasma spiked with analytes and IS
(LLOQ) and plasma sample 1 h after oral administration of Alismatis Rhizoma extract, respectively.
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shown in Fig. 3.
For matrix effect, all the ratios listed in Table 2 were within
the range 89.7e103.3%, indicating that no significant matrix ef-
fect was observed for alisol A and alisol B 23-acetate. Themean
matrix effect for the IS was 97.7% at a concentration of 5 ng/ml.
3.3.2. Linearity and LLOQ
The linearity was evaluated on three separate occasions with
two sets calibration curves per occasion. The calibration
curves showed the linearity was good over the concentration
range of 5.00e2500 ng/ml for alisol A and 5.00e2500 ng/ml forTable 2 e Summary of accuracy, precision, extraction recovery
plasma (n ¼ 6).
Analytes Concentration spiked
(ng/ml)
Intra-day RSD
(%)
Inte
Alisol A 25.00 2.9
300.0 3.3
4000 4.6
Alisol B 23-acetate 12.50 6.9
150.0 2.7
2000 5.9alisol B 23-acetate. Typical linear regression equations for the
calibration curves were as follows: y ¼ 0.0019x þ 0.0012
(r ¼ 0.9968) for alisol A; y ¼ 0.0034x þ 0.0022 (r ¼ 0.9977) for
alisol B 23-acetate, where y is the peak area ratio of the
analytes to the IS, and x is the plasma concentration of
analytes.
The LLOQ of analytes in plasma were 5.00 ng/ml with RSD
6.6% and RE 4.7% for alisol A, 5.0 ng/ml with RSD 7.8% and RE
9.0% for alisol B 23-acetate, for which the signal-to-noise ra-
tios were both above 10. The data above demonstrated that
this method was sensitive enough for the pharmacokinetic
study of alisol A, alisol B 23-acetate in vivo.and matrix effect of alisol A and alisol B 23-acetate in rat
r-day RSD
(%)
Accuracy
(RE, %)
Matrix effect
(%, RSD)
Extraction recovery
(%, mean ± SD)
6.8 2.5 99.5 ± 3.7 61.80 ± 0.50
7.4 6.6 94.1 ± 5.5 62.90 ± 1.20
3.5 6.3 96.3 ± 4.6 66.80 ± 4.10
4.3 1.4 89.7 ± 3.0 75.40 ± 5.60
7.1 8.1 93.8 ± 5.5 65.10 ± 4.00
8.8 6.0 103.3 ± 3.6 63.50 ± 4.50
Table 3 e Stability of alisol A, alisol B 23-acetate and diazepam in rat plasma at different conditions determined by UFLC-
MS/MS (n ¼ 3).
Analytes Concentration (ng/ml) 24 h, room
temperature
3 freeze-thaw
cycles
30 days, 20 C 8 h, 4 C
RE(%) RSD(%) RE(%) RSD(%) RE(%) RSD(%) RE(%) RSD(%)
Alisol A 25.00 3.9 6.4 1.0 3.6 6.4 4.8 7.2 4.6
300.0 2.3 7.5 9.1 7.3 4.5 2.4 9.6 4.0
4000 11.4 7.8 6.2 8.3 5.1 7.6 5.6 2.7
Alisol B 23-acetate 12.50 0.3 6.1 4.2 4.0 6.9 4.5 3.4 1.5
150.0 5.7 2.1 3.4 1.9 6.1 3.7 7.0 6.8
2000 4.6 1.1 2.0 1.8 3.1 4.2 10.2 5.7
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Intra-day precision, inter-day precision, and accuracy for ali-
sol A and alisol B 23-acetate are summarized in Table 2. All
results for the samples tested were within the acceptable
criteria of ±15%.
The extraction efficiencies at three concentrations (low,
medium, high) ranged from 61.80 to 66.80% for alisol A and
from 63.50 to 75.40% for alisol B 23-acetate (Table 2), which
indicated that recoveries of alisol A and alisol B 23-acetate
were consistent, and reproducible at different concentra-
tions. The mean extraction recovery of the IS was 94.5%.
3.3.4. Stability
The stability of alisol A and alisol B 23-acetate in rat plasma
under different conditions is summarized in Table 3. The re-
sults indicate that alisol A and alisol B 23-acetate were all
stable in plasma at room temperature for 24 h, at 20 C for at
least 7 days, after three freeze and thaw cycles, and 8 h after
prepared at 4 C during the analysis process.Fig. 4 e The concentrationetime curves of alisol A (a) and
alisol B 23-acetate (b) in rat plasma after oral
administration of Alismatis Rhizoma extract.3.4. Pharmacokinetic studies
The developed method has been successfully applied to a
pharmacokinetic study of alisol A and alisol B 23-acetate in rat
plasma after oral administration of alcohol extract of Alismatis
Rhizoma with a concentration of 2 g/ml (containing 1.4 mg/g
alisol A and 0.6 mg/g alisol B 23-acetate). The concen-
trationetime curves (mean ± SD) for alisol A and alisol B 23-
acetate are presented in Fig. 4 and the corresponding pharma-
cokineticdataare listed inTable4.TheT1/2andTmax inthispaper
have differences with the existing reports [14,15], this might be
caused by the extractionmethod, enterohepatic circulation and
different LLOQ and regions of Alisma orientale (Sam.) Juz.
After oral administration of alcohol extract of Alismatis
Rhizoma, alisol A and alisol B 23-acetate in rat plasma exhibit
similar pharmacokinetic behavior. Both of the concen-
trationetime curves of alisol A and alisol B 23-acetate showed
double-peak phenomenon [14,15]. The concentrationetime
curves showed that Alismatis Rhizoma was rapidly absorbed
in blood, then the concentration decreased slightly and
appeared a small peak. Following the first peak, the concen-
tration increased sharply within a short time, subsequently,
and the curves showed the second peaks which were much
higher than the previous one. The double-peak phenomenon
happens very often in the pharmacokinetic study of TCM
[18e21]. In this study, the phenomenon might be caused bythe following reasons: As for alisol A, simulated gastric fluid
has a low pH value of 1.4 approximately. Alisol B 23-acetate
contains epoxy heterocyclic which is extremely unstable,
and it can start the ring-opening reaction to generate alisol A
24-acetate by rearrangement in acidic condition readily.
Meanwhile, Alisol A can be obtained by deacetylation of alisol
A 24-acetate in acidic condition [22]. This might be the reason
of double peak of alisol A. As for alisol B-23 acetate, the double
peakmight result from the inter-transformed of alisol B or the
effect of enterohepatic circulation [14,22e25]. And further
studies need to be investigated.
Table 4 e Non-compartmental pharmacokinetic parameters for alisol A and alisol B 23-acetate in rat plasma after oral
administration of Rhizoma Alismatis extract (mean ± SD, n ¼ 6).
Analytes AUC(0-t)(mg h/l) AUC(0-∞)(mg h/l) Cmax(mg/l) T1/2(h) Tmax(h)
Alisol A 1549 ± 502 1739 ± 481 192.2 ± 40.9 9.28 ± 2.30 5.67 ± 0.82
Alisol B 23-acetate 3681 ± 679 3866 ± 700 427.7 ± 86.2 8.43 ± 1.97 5.67 ± 0.82
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In summary, a sensitive and efficient UFLC-MS/MSmethod for
simultaneous determination of alisol A and alisol B 23-acetate
in rat plasma has been developed and validated for the first
time in the work discussed in this paper. It was applied suc-
cessfully for the pharmacokinetic studies of oral administra-
tion of alcohol extract of Alismatis Rhizoma in rat plasma.
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